CIVIL ENGINEERING 365 ALL ABOUT CIVIL ENGINEERING


  • 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 2.

    Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi64–72.

    PubMed 

    Google Scholar
     

  • 3.

    Babcock BD, Aljehani MA, Jabo B, Choi AH, Morgan JW, Selleck MJ, et al. High-risk stage II colon cancer: not all risks are created equal. Ann Surg Oncol. 2018;25:1980–5.

    PubMed 

    Google Scholar
     

  • 4.

    eUpdate- Early Colon Cancer Treatment Recommendations, [Internet], ESMO Guidelines Committee, Lugano, Switzerland, 2019 [cited 2 January 2020]. Available from https://www.esmo.org/guidelines/gastrointestinal-cancers/localised-colon-cancer/eupdate-early-colon-cancer-treatment-recommendations.

  • 5.

    Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.

    PubMed 

    Google Scholar
     

  • 6.

    Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11:8332–40.

    CAS 
    PubMed 

    Google Scholar
     

  • 8.

    Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3:153–73.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 9.

    Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–87.e3.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 10.

    Wang T, Lee LH, Vyas M, Zhang L, Ganesh K, Firat C, et al. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Mod Pathol. 2019;32:1551–62.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 11.

    WHO Classification of Tumors Editorial Board. Digestive system tumors. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

  • 12.

    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Koenig JL, Toesca DAS, Harris JP, Tsai CJ, Haraldsdottir S, Lin AY, et al. Microsatellite instability and adjuvant chemotherapy in stage II colon cancer. Am J Clin Oncol. 2019;42:573–80.

    CAS 
    PubMed 

    Google Scholar
     

  • 14.

    Hansen TF, Kjaer-Frifeldt S, Eriksen AC, Lindebjerg J, Jensen LH, Sorensen FB, et al. Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. Br J Cancer. 2018;119:1367–73.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 15.

    Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002;236:416–21.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 16.

    Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med. 2016;374:211–22.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 17.

    Romiti A, Roberto M, Marchetti P, Di Cerbo A, Falcone R, Campisi G, et al. Study of histopathologic parameters to define the prognosis of stage II colon cancer. Int J Colorectal Dis. 2019;34:905–13.

    PubMed 

    Google Scholar
     

  • 18.

    Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, et al. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol. 2018;12:1639–55.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    Graule J, Uth K, Fischer E, Centeno I, Galvan JA, Eichmann M, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics. 2018;10:120.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 20.

    Suh E, Traber PG. An intestine-specific homeobox gene regulates proliferation and differentiation. Mol Cell Biol. 1996;16:619–25.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 21.

    Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303–10.

    PubMed 

    Google Scholar
     

  • 22.

    Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol. 2008;21:1403–12.

    CAS 
    PubMed 

    Google Scholar
     

  • 23.

    Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.

    CAS 
    PubMed 

    Google Scholar
     

  • 24.

    Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703–11.

    CAS 
    PubMed 

    Google Scholar
     

  • 25.

    Rosty C, Williamson EJ, Clendenning M, Walters RJ, Win AK, Jenkins MA, et al. Should the grading of colorectal adenocarcinoma include microsatellite instability status? Hum Pathol. 2014;45:2077–84.

    CAS 
    PubMed 

    Google Scholar
     

  • 26.

    Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009;48:368–76.

    CAS 
    PubMed 

    Google Scholar
     

  • 27.

    Stanisavljevic L, Assmus J, Storli KE, Leh SM, Dahl O, Myklebust MP. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer. Tumour Biol. 2016;37:7441–52.

    CAS 
    PubMed 

    Google Scholar
     

  • 28.

    Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget. 2017;8:87837–47.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    NordiQC: assessments and recommended protocols, [Internet], Nordic immunohistochemical Quality Control (NordiQC), Aalborg, Denmark 2016 [cited 13 June 2020]. Available from https://www.nordiqc.org/downloads/assessments/83_39.pdf.

  • 30.

    Chen W, Frankel WL. A practical guide to biomarkers for the evaluation of colorectal cancer. Mod Pathol. 2019;32 Suppl 1:1–15.

    PubMed 

    Google Scholar
     

  • 31.

    Sarode VR, Robinson L. Screening for Lynch syndrome by immunohistochemistry of mismatch repair proteins: significance of indeterminate result and correlation with mutational studies. Arch Pathol Lab Med. 2019;143:1225–33.

    CAS 
    PubMed 

    Google Scholar
     

  • 32.

    Joost P, Veurink N, Holck S, Klarskov L, Bojesen A, Harbo M, et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol. 2014;9:126.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    McCarthy AJ, Capo-Chichi JM, Spence T, Grenier S, Stockley T, Kamel-Reid S, et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2019;5:115–29.

    CAS 
    PubMed 

    Google Scholar
     

  • 34.

    Team RDC. R: a language and environment for statistical computing. Vienna: Team RDC; 2017.

  • 35.

    Pilati C, Taieb J, Balogoun R, Marisa L, de Reynies A, Laurent-Puig P. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. Ann Oncol. 2017;28:1032–5.

    CAS 
    PubMed 

    Google Scholar
     

  • 36.

    Olsen J, Eiholm S, Kirkeby LT, Espersen ML, Jess P, Gogenur I, et al. CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer. Exp Mol Pathol. 2016;100:59–66.

    CAS 
    PubMed 

    Google Scholar
     

  • 37.

    Lundberg IV, Edin S, Eklof V, Oberg A, Palmqvist R, Wikberg ML. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer. 2016;16:471.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Bae JM, Lee TH, Cho NY, Kim TY, Kang GH. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2015;21:1457–67.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Slik K, Turkki R, Carpen O, Kurki S, Korkeila E, Sundstrom J, et al. CDX2 loss with microsatellite stable phenotype predicts poor clinical outcome in stage II colorectal carcinoma. Am J Surg Pathol. 2019;43:1473–82.

    PubMed 

    Google Scholar
     

  • 40.

    Kim JH, Rhee YY, Bae JM, Cho NY, Kang GH. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. Am J Surg Pathol. 2013;37:1532–41.

    PubMed 

    Google Scholar
     

  • 41.

    Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, et al. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res. 2009;15:4665–73.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 42.

    Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, et al. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Mod Pathol. 2019;32:1217–31.

    CAS 
    PubMed 

    Google Scholar
     

  • 43.

    Knosel T, Chen Y, Hotovy S, Settmacher U, Altendorf-Hofmann A, Petersen I. Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis. 2012;27:1391–9.

    PubMed 

    Google Scholar
     

  • 44.

    Ryan EJ, Creavin B, Khaw YL, Kelly ME, Mohan HM, Geraghty R, et al. Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer. BJS Open. 2018;2:456–63.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 45.

    Liu Q, Luo D, An H, Zhang S, Cai S, Li Q, et al. Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer. J Cancer. 2019;10:1209–15.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    CAS 
    PubMed 

    Google Scholar
     

  • 47.

    Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer. 2009;101:1282–9.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     



  • Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *